2026-07-10 22:00:00
Separate teams discovered the same target in solid cancers, enabling a powerful two-pronged attack on both tumors and the cells shielding them.
Cancer researchers just found a new way to take on tumors.
CAR T cell therapy revolutionized blood cancer treatment by supercharging a patient’s own immune cells to hunt down cancers. But the approach has struggled in solid cancers. These are some of our top killers—breast, lung, prostate. Roughly two million Americans are expected to be diagnosed with cancer in 2026, and over 600,000 will likely succumb to the disease.
Unlike blood cancers, solid tumors rarely share a single, universal target for CAR T cells. Even cells within the same tumor are a mishmash. Some have little or none of a target protein, allowing them to evade the engineered immune cells, survive treatment, and fuel relapse.
“Target discovery remains a considerable challenge in the development and translation of
CAR T cell therapies for solid tumors,” wrote Christopher Mount and Marcela Maus at the Massachusetts General Brigham Cancer Institute.
Now, two independent teams have converged on the same promising target: A cell-surface protein called GPNMB. In one study, CAR T cells engineered to recognize GPNMB rapidly destroyed glioblastoma—a lethal brain cancer—in tissues taken from patients and shrank tumors in mice.
A second team used a similar strategy against an aggressive soft tissue cancer to fight tumors in organoids and mice. In an early clinical trial involving a single participant, one infusion stabilized the disease for three months without serious side effects.
CAR T designers are often wary of broadly shared targets because they can trigger dangerous attacks on healthy tissue. But GPNMB is an odd duck. In addition to cancer cells, it also sits on immune cells that spur cancer growth or suppress the body’s innate ability to get rid of tumors.
“Our approach attacks both the tumor and the environment that allows it to thrive,” said Sheila Singh at McMaster, who led the glioblastoma study, in a press release. “We’re going beyond targeting the cancer alone and eliminating the immune cells that help shield it from treatment.”
Solid cancers have plenty of tricks to outsmart CAR T cells.
Researchers make these supercharged immune cells by extracting a patient’s own T cells and genetically engineering them to produce protein “claws” that latch onto a specific cancer target. After infusing the cells back into the body, they seek and destroy tumor cells. CAR T has transformed treatment for several blood cancers and is showing promise in autoimmune diseases and excessive heart and kidney scarring. To simplify the procedure, researchers are also exploring ways to directly transform T cells inside the body with gene therapy.
Solid cancers, however, are far tougher opponents. Unlike blood cancers, which are heavily coated with a shared target called an antigen, solid tumors are molecular patchworks. Cells within the same tumor can display different targets—or none at all—allowing some to evade a CAR T attack and trigger relapse. Many of these targets also appear on healthy tissues, raising the risk of dangerous side effects. And then there’s the tumor microenvironment: A toxic, glue-like “fortress” that hijacks immune cells and uses them to battle incoming CAR T cells.
These barriers aren’t impenetrable. Previous work enlisted bacteria to help CAR T cells burrow into tumors. Other efforts engineered ultra-sensitive CAR T cells capable of detecting tiny amounts of a cancer target shared across multiple solid tumors.
“Recent reports of activity in several clinical trials reinforce optimism that these efforts may result in true clinical benefit,” wrote Mount and Maus, who were not involved in either study.
But these strategies require additional engineering steps, increasing complexity and cost. And most still leave one major roadblock intact: The tumor’s immune defenses.
In the glioblastoma study, the team at McMaster University scoured donated tumors for proteins that distinguished the most aggressive cancer cells. They found one standout: GPNMB. Another test of every protein dotting the cell surface confirmed it as a promising target. The protein is evident across a cancer cell’s membrane, making it readily accessible to CAR T cells.
In lab tests, CAR T cells engineered against GPNMB performed well, nearly eliminating tumors grown from patient samples and extending survival in mice.
The target turned out to be far more valuable than expected. The team soon realized that GPNMB also marked the immune cells that suppress anti-cancer drugs. CAR T cells attacked both fronts simultaneously, weakening the tumor’s immune shield and killing the cancer itself.
“Most approaches have focused on killing cancer cells alone,” said study author Shan Grewal. “Our work suggests we may also need to dismantle the immune support system that helps the tumor survive.”
The second team focused on alveolar soft-part sarcoma, a rare soft-tissue cancer that often spreads to the lungs, brain, and bones before it’s diagnosed. Treatment often comes too late.
The disease is driven by a type of “fusion” gene created when pieces of genetic material are accidentally stitched together. These genes are extremely tough to target directly. Instead, the team screened all surface proteins on the cancer cells and again landed on GPNMB as a top candidate for intervention. The protein’s levels closely tracked the activity of the fusion gene.
CAR T cells targeting GPNMB cleared tumors and prevented metastasis in mice. But because an earlier antibody drug against the protein caused severe skin toxicity in patients, the team also tested their CAR T cells in mice carrying small human skin grafts. Although inflammation initially flared, there were no signs of ongoing skin damage.
Encouraged, the team treated a patient with relapsed, metastasized alveolar soft-part sarcoma. After a single infusion, the engineered cells rapidly divided in the bloodstream and remained detectable for roughly a month. The treatment didn’t trigger skin rashes or more dangerous side effects, like cytokine release syndrome where the body mounts a hyperactive immune defense that harms healthy organs.
The treatment’s benefits outlasted the engineered cells themselves. For roughly three months, imaging tests found fewer of the small, round spots on the patient’s lungs that often signal metastatic cancer, suggesting the disease had stabilized.
A final analysis identified another roadblock: Clusters of cells that suppress the immune system and could blunt the benefits. Adding drugs to block these immune molecules boosted tumor killing in mice. Because the same kind of gene fusion drives other cancers, including kidney, the CAR T cells could have reach beyond this specific type of sarcoma.
Together, the studies underscore that the best CAR T targets might extend beyond cancer cells to expose and attack cancer’s immune cell supporters too. Finding a viable target is a delicate balancing act. Chosen well, and CAR T cells could tackle multiple drivers for cancer growth. Choose poorly, and healthy tissues could get hurt in the crossfire.
Even so, “these two studies indicate that GPNMB represents an actionable target for CAR T cell therapies in several solid tumors,” wrote Mount and Maus.
The post CAR T Revolutionized How We Treat Blood Cancers. Now It’s Closing In on Solid Tumors. appeared first on SingularityHub.
2026-07-10 06:34:39
SpudCell is a big step toward synthetic biology’s dream of building life from scratch.
Synthetic biologists have long dreamed of constructing artificial cells from the bottom up. Researchers have now taken a major step in this direction by demonstrating that non-living components can be assembled into a system that grows, copies its DNA, and divides.
The genomic revolution transformed our ability to understand and manipulate cellular machinery, allowing scientists to rewire cells’ genetic circuitry to fight disease, produce valuable chemicals, and make crops more resilient. The holy grail for the field, however, has been to use these tools to create entirely synthetic cells—a milestone that would signal humanity’s mastery of life’s key ingredients.
How best to do this has long been an open question. Genomics pioneer Craig Venter made significant progress by stripping living bacteria back to their bare essentials, culminating in the 2016 unveiling of a minimal cell with just 473 genes. The Synthetic Yeast Genome Project has taken the opposite approach, building artificial versions of all 16 yeast chromosomes from scratch, though they’ve yet to get them working together in a single cell.
Now, researchers from the University of Minnesota, have assembled a synthetic cell out of engineered, non-living components housed inside an artificial, cell-like membrane. Their creation was capable of the four hallmarks of a living entity—the ability to feed, grow, copy genetic material, and produce offspring.
“We’ve replicated in chemistry what only used to be possible in biology: the complete set of behaviors of a cell,” Kate Adamala, who led the project, said in a press release. “It proves that the most fundamental functions of life, like growth and replication, do not need a mysterious magical spark.”
The researchers outline the design for their synthetic organism—nicknamed SpudCell for its potato-like shape under the microscope—in a non-peer reviewed paper uploaded to bioRxiv. SpudCell features a genome 90,000 base pairs long, which is considerably smaller than the 113,000 base pairs researchers had previously predicted would be the bare minimum needed to support a viable cell.
Rather than housing all the genes in a single chromosome, the team split them across several small, circular DNA molecules called plasmids, each specialized to fulfill specific functions. The researchers say this makes it possible to modify different aspects of the organism more easily.
To read the genome and build proteins, SpudCell uses a pre-defined kit of 36 purified enzymes drawn largely from E. coli. The whole assembly sits inside a liposome, a hollow bubble of the same fatty molecules that form natural cell membranes.
The artificial cell feeds in two distinct ways. Small molecules pass directly into the cell through protein pores implanted across the membrane. Molecules too large to squeeze through—like ribosomes and enzymes—are packaged inside tiny lipid bubbles that fuse with the membrane and empty their contents inside.
While the cell can feed, it’s entirely reliant on the researchers providing it with specially prepared meals. This means it’s a long way from surviving in the wild, which is both a major limitation and a key safety mechanism. “It’s a bed-ridden Frankenstein’s monster that has to be spoon-fed,” Adamala told New Scientist. “There’s no danger of it running amok.”
After ingesting “food,” SpudCell’s genes use the material to churn out proteins, while folding the incoming lipids into its membrane. This causes the whole cell structure to swell. Within a few hours, it’s bulked up enough to reproduce by dividing into two smaller cells.
Replicating cell division has been a longstanding challenge in the field. Natural cells split using an intricate protein scaffold called a cytoskeleton that’s fiendishly difficult to recreate. Adamala’s team sidestepped this problem by using a completely different mechanism, in which proteins bunch up on the membrane’s surface, putting it under mechanical strain. Eventually this squeezes two parts of the membrane together to pinch off a new cell.
The cells even manage a crude form of evolution. When the researchers introduced a genetic tweak boosting the cells’ ability to feed, those with the variant outcompeted the original lineage within five generations, and their edge widened when the researchers exposed the population to nutrient scarcity.
However, no one is claiming SpudCell is alive. Crucially, the cells cannot make their own ribosomes—the machines that build proteins from genetic instructions—and the ribosomes provided by the researchers degrade over time, limiting the cells to five to ten divisions.
The University of Chicago’s Jack Szostak told Quanta the work is an “impressive step” but the inability to produce ribosomes seriously limits potential for sustained growth. “If their system was able to generate its own ribosomes and other proteins and RNAs, it would be much closer to existing biological cells such as bacteria,” he said.
Nonetheless, the researchers think these artificial cells are a promising way to manufacture drugs, fuels, and materials without the toxic, energy-hungry industrial chemistry we rely on today. And they’ve created a new nonprofit called Biotic to share the tools they’ve developed with researchers.
The post This Synthetic Cell Grows, Copies Its DNA, and Produces Offspring—But It Isn’t Alive appeared first on SingularityHub.
2026-07-07 22:00:00
Scientists used AI to find targets shared by thousands of related viruses and build what they hope is a universal vaccine.
Researchers at the University of Cambridge have developed what they describe as a fundamentally new type of vaccine using artificial intelligence. The vaccine’s key component was designed entirely by AI and has now been tested in people for the first time.
The goal is ambitious: a single vaccine that works not just against all known human coronavirus variants, but against related bat viruses that could jump from animals to humans and cause future pandemics.
Traditional vaccines train our immune system to recognize one specific virus. The problem is that viruses mutate. When they change enough, the vaccine stops working, which is why we need a new flu shot every year and why Covid vaccines have been updated repeatedly since 2021.
AI offers a way around this. By analyzing genetic data from thousands of related viruses, it can identify the parts that stay the same across different strains and that are unlikely to change over time. Target those stable features, and you have a vaccine that should work against the whole family, not just the strain you started with.
This is exactly what the Cambridge team did. They used AI to scan viruses from the sarbecovirus family, which includes the viruses that cause both SARS and Covid, as well as a range of animal coronaviruses—looking for shared features that evolution has left largely untouched. Those features became the basis of the vaccine.
While many people are familiar with the mRNA shots used during the pandemic, this new vaccine uses DNA. DNA vaccines are generally more stable than mRNA vaccines, making them easier to store and transport. This is a significant advantage in lower-income countries where “cold-chain” infrastructure is limited.
They can also be administered without needles. A high-pressure stream of liquid delivers the vaccine through the skin, making administration less painful and easier to scale up during an outbreak.
These practical advantages matter most if the vaccine itself can do something no existing jab can: protect against viruses we haven’t encountered yet.
Broad-spectrum vaccines could change the way the world responds to emerging infectious diseases. By offering much wider protection than traditional vaccines, they could provide rapid immunity against new and emerging viral threats. This would equip public health officials with tools to stop future outbreaks in their tracks before they have a chance to turn into global pandemics.
They could also transform our approach to more familiar diseases. Influenza is a prime target because it exists in many different strains and evolves so rapidly. Scientists have to predict which strains will dominate each flu season, and if they guess wrong, vaccine effectiveness can suffer. A universal flu vaccine that targets features shared across multiple strains could eventually end the annual race to keep up with the virus.
The Ebola virus shows why this matters right now. The recent outbreak in the Democratic Republic of the Congo and Uganda is driven by the Bundibugyo strain, which bypasses existing vaccines. While researchers rush to create a new vaccine specifically for this strain, local communities remain at high risk. A broad-spectrum vaccine designed to cover an entire virus family could transform that picture.
This is the first human trial of an AI-designed vaccine. The results showed that this DNA vaccine was able to stimulate the immune system to produce antibodies that can recognize different types of sarbecoviruses. The technology was found to be safe and well tolerated.
This is an exciting advance because it demonstrates how AI has the potential to design variant-proof vaccines against future pandemic threats. The needle-free delivery system could also make the vaccine easier to administer and distribute worldwide.
However, there is more work to do. Although the results in this study are encouraging, the immune responses following vaccination were modest. It was also uncertain how long the protection lasts and whether further boosters will be required. Larger trials are also needed to determine whether the vaccine can prevent or reduce viral infections in the real world.
A universal vaccine remains a few years away. And any new vaccine must still pass larger trials to prove it is safe, effective, and provides lasting protection. But this study shows the goal is getting closer—and AI may help us get there faster.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
The post The First AI‑Designed Vaccine Has Been Tested in People. Here’s What Happened. appeared first on SingularityHub.
2026-07-06 22:00:00
Similar concepts in different languages share an address in the brain.
My octogenarian father-in-law is trilingual and a lifelong fan of the World Cup. As he cheers on his favorite teams in English, Spanish, or French—sometimes switching between them mid-sentence—I’m always amazed at how easy it seems.
Scientists have long been fascinated by the brain’s ability to learn and retain multiple languages. Even after years of disuse, a brief exposure can quickly revive a language without having to consciously relearn its grammar or vocabulary. Bilingualism may offer other cognitive perks. Small studies suggest it delays brain aging, lowers dementia risk, and provides a slight edge in executive function (the ability to stay focused on a goal).
But most of the evidence is from brain imaging studies that offer only a bird’s-eye view of neural activity and miss the finer details.
Now, scientists from the Baylor College of Medicine and collaborators have recorded activity from single neurons in four bilingual volunteers with epilepsy as they listened, read, and spoke in English and Spanish. The participants already had electrodes implanted in the hippocampus—a brain region critical for learning and memory—to track the source of their seizures.
“This is the very first study to look at how bilingual brains work at the level of individual neurons, and to do so in real time,” said study author Xinyuan Yan in a press release.
The results suggest the bilingual brain operates on two levels. Individual neurons often showed a strong preference for one language when participants heard or spoke words with the same meaning. But networks of neurons were largely language independent. They spontaneously organized into a concept map, placing words with related meanings—such as “dog” and “wolf”—closer together than unrelated words like “fork.”
Surprisingly, both languages relied on the same underlying map. Using the English concept map alone, the team could accurately predict clusters of related Spanish words.
“It’s like looking into a room from a different window. Everything inside is the same, but the perspective is different,” said study author Sameer Sheth.
Language is central to human connection. Although some words don’t directly translate, people can express the same ideas across multiple languages without losing their core meaning.
Children raised in multilingual households are especially adept at switching between languages, often blending words and phrases together. Even when languages differ dramatically in grammar, syntax, and pronunciation, the brain somehow keeps their structures distinct while fluidly merging their meanings.
Long before we learn to speak, neural networks transform thoughts into electrical patterns that form words and sentences. Because languages are built differently—for example, where a verb falls in a sentence—it seems reasonable that each language would have a unique neural fingerprint.
But that might not be the case. A recent AI-powered analysis of functional MRI (fMRI) scans from monolingual speakers of 21 languages suggested that languages share a similar neural scaffold that represents meaning and concepts. Even fictional languages, including Klingon from Star Trek and Na’vi from Avatar, appear to tap into the same underlying system.
A growing body of evidence from bilingual speakers echoes these findings. One fMRI study found native Chinese speakers learned English more efficiently when they recruited brain networks used for Chinese. Another study identified shared speech-related brain activity sufficient for decoding words across languages.
Despite hinting at a universal language map, these standard imaging technologies struggle to capture detailed patterns as people switch languages in real time. To see how bilingual brains actually pull off the feat, we need to listen in on single cells.
The team studied four volunteers fluent in English and Spanish. All had learned the languages before age five and continued to use them regularly. Each also had electrodes implanted in the hippocampus to monitor seizures as part of epilepsy treatment, allowing researchers to track individual neuron activity as they listened and spoke.
Though often overlooked in language research, the hippocampus is increasingly recognized as a hub for word meaning, and it may also link concepts together. Here, the team monitored more than 100 neurons in each participant as they completed three language tasks.
First, the participants listened to roughly an hour of YouTube videos and the audiobook Eat Pray Love (Come Reza Ama). Next, they read aloud nearly 100 phrases displayed on a screen, such as “let’s have fun” and its Spanish equivalent “vamos a divertirnos.” Finally, they spent up to 90 minutes chatting with native speakers of each language, discussing everything from family to their epilepsy journey.
By the end, the team had compiled thousands of spoken words, hundreds of matched phrases, and hours of natural conversation.
Only a handful of neurons appeared truly bilingual, responding similarly to equivalent words such as “friends” and “amigos.” To better interpret the neural activity, the team turned to mBERT, Google’s multilingual language model that understands more than 100 languages. Like other LLMs, the model represents words according to their relationships and context rather than simple dictionary definitions.
The comparison revealed a similar pattern in brains and machines. Individual neurons rarely encoded the same word across languages. Instead, meaning emerged at the population level.
Both neural activity and mBERT tracked broader context, organizing words into an abstract conceptual landscape called semantic geometry. In this map, related concepts cluster together—“cat” sits closer to “dog” than to “galaxy,” for example—even if the precise features defining those relationships are unclear.
Yet the map remained largely unchanged across languages, suggesting it captured a fundamental mechanism for language processing in the brain. Using the English map alone, the team could predict which Spanish words would cluster around “perro” (or “dog”).
“This is how the brain encodes the meaning of words across languages,” said Yan. “It doesn’t rely on individual neurons translating individual words, but groups of neurons adjusting their activities to create the similar pattern for equivalent words in both languages.”
The study focused on semantics, or meaning, as opposed to syntax, the rules governing sentence structure. A recent study also using single-cell recordings from people with epilepsy suggests that other groups of neurons, particularly those in the frontal parts of the brain, may specialize in grammar while ignoring semantics. Whether they also share a “map” across languages remains to be seen.
The next step is to watch these maps emerge. The team hopes to track people as they learn a new language, revealing how new words and concepts are woven into semantic landscapes in real time. The results could deepen our understanding of one of the most fundamental communication skills and even inspire more capable and efficient language models in AI.
“Our study shows that the brain is wired to learn multiple languages,” said study author Benjamin Hayden.
The post How the Bilingual Brain Switches Languages With Ease appeared first on SingularityHub.
2026-07-03 22:00:00
The night sky seems eternal and unchanging. But in cosmic time, nothing could be further from the truth.
Vasily Belokurov is one of three winners of the 2026 Kavli Prize in Astrophysics. The award is for uncovering fossil evidence of past galactic mergers that prove how the Milky Way evolved.
No matter the time or vantage point, from a pre-Neolithic cave to a post-lockdown London high-rise, the predictability of the night sky has always been humanity’s symbol of permanence and reassuring stability.
Yet this apparent calm is deceptive. Our galaxy, the Milky Way, emerged from chaos and turbulence, and its constellations are full of migrants, exiles and survivors. Right now, it has begun to stretch and distort again, pulled by a massive companion and heading for an inevitable collision.
How can I be so sure? As a galactic archaeologist, my job is to reconstruct the past of our galaxy and read the signs of its future.
Instead of digging through soil, I use the laws of dynamics and stellar evolution to sift through hundreds of millions of stars—searching for the most ancient and chemically peculiar among them, interpreting their orbits and piecing together the events that shaped the Milky Way. One ancient encounter left scars so deep that, billions of years later, they still define the galaxy around us.
I want to understand what governs the lives of these massive cosmic systems: which changes are nature—the slow internal evolution of a galaxy disk—and which are nurture, imposed by collisions and mergers.
Questions about the source of dark matter underpin it all. This is the invisible substance whose gravity holds galaxies together, but whose true identity remains one of the greatest unsolved puzzles in astrophysics.
The Milky Way is the one galaxy where stellar motions can be measured in extraordinary detail. This allows cosmologists including myself to construct our most precise map yet of dark matter: how far it reaches, how dense it is around the sun, what shape it has, and how smooth or lumpy it may be. If we can build this map in enough detail, we may begin to understand not just where dark matter is, but what it is.
Our work has been transformed by a revolution in open sky surveys. From 2000, the Sloan Digital Sky Survey showed what becomes possible when vast astronomical datasets are made public, enabling discoveries far beyond the goals for which the survey was first built.
And since 2014, Gaia, the European space telescope, has taken this transformation to another level by mapping the positions and motions of nearly 2 billion stars, turning the galaxy into a vast archaeological record. No ruins, no shards, and no bones—only stars that hold the clues.
The clearest giveaway that something cataclysmic took place long ago in our galaxy is the migrants we observe: stars that were not born in the Milky Way.
While native stars mostly travel together, circling the galactic center in the great rotating flow of the disk, migrants cut across that order. They slide past the locals, plunge into the inner galaxy, then fly back out to its outskirts, again and again.
These unusual orbits go hand-in-hand with unusual chemistry. Most of the migrant stars are less enriched in heavier elements than the locally born population. Their chemical composition is a sign of a slower rate of evolution that is typical of a dwarf galaxy.
This makes the migrants doubly valuable. They are both fossils of the Milky Way’s violent past and probes of its outer regions, traveling where the local stars rarely go.
One of the central ideas in the theory of cosmic structure formation is that galaxies grow hierarchically. Smaller galaxies fall into larger ones and are torn apart, leaving their stars behind as migrants.
In the Milky Way, the largest ancient structure of this kind is known as Gaia-Sausage-Enceladus. It is the remains of a vanished galaxy that collided with our own between 8 and 11 billion years ago (the “sausage” refers to a pattern in its stars’ motions).
The Milky Way also did not go through that crash unscathed. The collision rewired and reshaped it.
Some of these changes are easily visible in the data. Stars from the old disk were splashed into our galaxy’s halo, becoming exiles in the place where they were born. A new posse of star clusters were also acquired.
At the same time, we think something even more momentous was taking place. The encounter changed the orientation of the Milky Way’s disk, and its alignment with the dark matter halo.
While dark matter is too diffuse to dominate our solar system, in the outer galaxy it is the main gravitating mass—moving, streaming, and in the standard picture, clumping into a hierarchy of lumps.
Around the Milky Way, this dark matter forms a vast halo, much larger than the luminous part of our galaxy. We often imagine this halo as a sparse, round cloud, but Gaia has helped show this picture is too simple.
The dark halo can be stretched out of shape by a major encounter. Like a ship beginning to list, the Milky Way started to lean—not suddenly, not visibly, but over billions of years.
Unusually, compared with many galaxies of similar mass, the Milky Way was allowed ample time to recover from the shock of the “sausage merger.” No other cosmic cataclysm appears to have shaken our galaxy since, letting it settle into a quiet, uneventful life. That is, until now.
The Large Magellanic Cloud (LMC), currently our galaxy’s most massive companion, is already pulling at the Milky Way, disturbing its halo again. In an echo of what happened some 10 billion years ago, the Milky Way is being drawn into an accelerating dance with this neighboring dwarf galaxy, recoiling in response to the LMC’s approach.
This is a dance that only one galaxy is likely to survive intact. A new chapter of migration, survival and adaptation has begun.
None of this spoils the beauty of the night sky—it deepens it. The calm band of light above us is not a symbol of permanence, but the visible reminder of a long survival.
The Milky Way has been broken, rebuilt, and is now being disturbed again. Its stars remember the past; their motions reveal the future. What looks eternal is, in truth, a moment in a much longer story.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
The post The Milky Way Was Rewired by a Cataclysmic Collision Billions of Years Ago. Now It Is on Course for Another. appeared first on SingularityHub.
2026-07-02 22:00:00
A single observational case suggests psilocybin may ‘awaken’ cognitive reserve in dementia. But scientists caution controlled trials are needed to know if the drug was the cause.
For five years, Alzheimer’s slowly stripped away a Japanese-American woman’s ability to speak more than one syllable at a time. The woman, now in her 80s, was diagnosed roughly a decade ago, and her condition steadily worsened. She struggled to walk and recognize family members.
Then, under medical supervision, she took a large dose of mushrooms containing the psychedelic psilocybin. Within three days, her symptoms had improved. She began spontaneously recounting memories and initiating conversations in full sentences. Her alertness returned, and she could move around independently.
A week later, she was recognizing family members, asking where they were, and pointing out cars that seem out of place.
Psilocybin has been maligned for decades. But renewed interest in its unique effects on the brain has pushed it into mainstream research. Early studies suggest it may help treat depression, anxiety, addiction, post-traumatic stress disorder, and other psychiatric conditions. A clinical trial is underway to gauge whether it can protect the aging brain.
The case study, conducted in Brazil, adds to that momentum. The team emphasizes that it describes a single patient and is purely observational. Because of the severity of her disease, they could not perform brain scans, measure biomarkers, or conduct standard cognitive tests. Exactly why her symptoms improved remains unknown.
Even so, they propose that psilocybin may have temporarily unlocked brain function in late-stage Alzheimer’s, potentially allowing dormant neural networks to rewire.
Alzheimer’s is often synonymous with memory loss. Sadly, symptoms range far beyond forgetting names or misplacing glasses.
As the disease progresses, people gradually struggle to find the right words or follow conversations. Their ability to tackle everyday tasks—cooking, managing finances, planning ahead—erodes. Depression, irritability, and anxiety often emerge. Over time, their personalities flatten, leaving them less outgoing, engaged, or empathetic.
These stories are far too common. According to the World Health Organization, roughly 57 million people worldwide were living with dementia in 2021. Alzheimer’s may account for up to 70 percent of cases. As populations age, that number is expected to climb.
Alzheimer’s has no single cause. Genetics likely play a role. Some gene variants are linked to early-onset forms of the disease, an area scientists are now tackling with gene therapy.
Another hallmark of the disease is a buildup of abnormal protein clumps, or plaques, in and around neurons, which disrupts normal function and wrecks their ability to form neural networks supporting memory and cognition. Years of efforts to remove plaques have largely failed, though the FDA recently approved two antibodies that reduce them and modestly slow cognitive decline.
Then there’s inflammation. In Alzheimer’s, the brain’s immune system can become overactive. Rather than responding only to damage, inflammation drives disease progression, spreading toxic protein clumps through the brain and further damaging its ability to form new connections.
Here’s where psilocybin, the active ingredient in magic mushrooms, may help. Psilocybin alters serotonin signaling, a brain chemical involved in mood, perception, and cognition. But its effects likely extend far beyond that.
Studies in mice suggest the chemical boosts the brain’s ability to rewire, a process known as neuroplasticity. Human brain imaging studies have found that the psychedelic temporarily reorganizes communication between large brain networks, changing how distant regions interact. In some participants, supervised treatment has been linked to greater cognitive flexibility, deeper self-reflection, and improved well-being.
Other studies hint at a protective role. Psilocybin triggers the release of “nurturing” proteins. This process helps neurons survive stress and extend their branching connections. It’s these delicate structures that build up neural networks, and they wither away during depression, aging, and dementia. Inside the hippocampus, a region crucial for learning and memory, the drug stimulates the birth of new neurons, at least in mice.
Given its positive effects on brain plasticity, psilocybin is now being tested in multiple psychiatric disorders characterized by unusually rigid patterns of brain activity. Older adults remain largely absent from these studies, even though they could benefit the most.
Before treatment, the woman struggled with everyday life. For five years, she could communicate using only single-syllable words. Her mobility was severely limited, and she struggled with incontinence.
With the consent of her caretaker, she received five grams of the Enigma strain of Psilocybe cubensis. Because psilocybin levels vary widely between mushrooms, the exact dose is unknown. But compared to other clinical trials, it was relatively high.
The team chose the dose “based on prior experiential observations regarding depth and duration of psychedelic-induced neurobehavioral effects,” wrote the team.
Initially, the woman fell into a deep sleep-like state accompanied by elevated body temperature and heavy sweating. Roughly 19 hours later, she suddenly awoke and began speaking to caregivers in complete sentences, recounting memories from her life. The conversation lasted around four hours.
Over the following days, she became increasingly alert and engaged. She recognized family members, regained mobility, and could pick out matching clothes to dress herself. A week later, she was noticing small details in her environment, including a rental car parked outside the house. When a family member was absent, she asked, “Where did Celso go?” She also seemed to rediscover her love of social interactions, making eye contact, smiling back, and actively starting conversations.
A month after the initial session, she returned for a second supervised dose of three grams. After the second dose, she became even more verbally expressive, displayed a sense of humor, and described memories of surfing with her son on a peaceful island. Throughout the trial, the drug alleviated incontinence and improved her quality of life.
The results come with major caveats. The improvements were observational and largely reported by caregivers, leaving room for bias. The team didn’t administer standardized tests for cognition, dementia, depression, and anxiety. Nor did they perform brain scans or monitor sleep, making it impossible to determine what brain changes were behind her apparent “awakening.”
“Causality cannot be established, and spontaneous fluctuations inherent to neurodegenerative disease cannot be completely excluded,” they wrote.
But the study touches on a provocative idea in Alzheimer’s: Cognitive reserve. The theory proposes some people can tolerate greater levels of harm to the brain and continue functioning despite significant damage. Psilocybin may have temporarily tapped into these reserves, allowing dormant neural circuits to engage and rewire to compensate for impaired ones. The hypothesis is highly speculative and needs to be rigorously tested.
Meanwhile, a clinical trial is investigating whether psilocybin can reduce depression and improve quality of life in people with mild cognitive impairment or early Alzheimer’s disease, moving the needle beyond a single case study.
For one family, however, the benefits are already substantial. At a follow-up visit, the woman spontaneously said to everyone in the room, “It is pleasant to come here.”
The post Woman With Alzheimer’s Shows Striking Improvement After Taking Magic Mushrooms appeared first on SingularityHub.
